Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy
Black Diamond Therapeutics maintains a strong cash position, sufficient to fund operations into H2 2028. I rate BDTX stock as Buy. Read my complete analysis.